Resonance Health (ASX:RHT) FCF Margin %: 0.41% (As of Dec. 2025)


What is Resonance Health FCF Margin %?

Resonance Health ASX:RHT +4.55% FCF Margin % is 0.41% as of Dec. 2025. The stock has 6 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Resonance Health ranks worse than 62.48% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Resonance Health's Free Cash Flow for the six months ended in Dec. 2025 was A$0.03 Mil. Resonance Health's Revenue for the six months ended in Dec. 2025 was A$7.98 Mil. Therefore, Resonance Health's FCF Margin % for the quarter that ended in Dec. 2025 was 0.41%.

As of today, Resonance Health's current FCF Yield % is -0.70%.

The historical rank and industry rank for Resonance Health's FCF Margin % or its related term are showing as below:

ASX:RHT' s FCF Margin % Range Over the Past 10 Years
Min: -56.4   Med: -0.1   Max: 34.95
Current: -1.11

During the past 13 years, the highest FCF Margin % of Resonance Health was 34.95%. The lowest was -56.40%. And the median was -0.10%.

ASX:RHT's FCF Margin % is ranked worse than
62.48% of 669 companies
in the Healthcare Providers & Services industry
Industry Median: 3.34 vs ASX:RHT: -1.11

Resonance Health FCF Margin % Related Terms

Resonance Health FCF Margin % Historical Data

* Premium members only.

The historical data trend for Resonance Health's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Resonance Health FCF Margin % Chart

Resonance Health Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.46 -56.40 -14.19 11.76 5.65

Resonance Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.77 26.80 15.57 -3.17 0.41

ASX:RHT vs VEEV, BTSG, TEM: FCF Margin % Comparison

For the Health Information Services subindustry, Resonance Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Resonance Health FCF Margin % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Resonance Health's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Resonance Health's FCF Margin % falls into.


Resonance Health FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Resonance Health's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Jun. 2025 )/Revenue (A: Jun. 2025 )
=0.626/11.073
=5.65 %

Resonance Health's FCF Margin for the quarter that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=0.033/7.975
=0.41 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.41% mean?
Resonance Health (ASX:RHT) has a FCF Margin % of 0.41% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Resonance Health and its competitors. According to the industry distribution chart, Resonance Health ranks #418 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 62.5%.
Is Resonance Health's FCF Margin % too high?
Resonance Health's current FCF Margin % is 0.41%. The Healthcare Providers & Services industry median FCF Margin % is 3.34. Resonance Health's value of 0.41% is 87.7% below this industry median. Based on the distribution chart, Resonance Health ranks #418 out of 669 companies in the Healthcare Providers & Services industry, which is below the industry midpoint.
How does Resonance Health's FCF Margin % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Resonance Health ranks #418 out of 669 companies for FCF Margin %. This places Resonance Health in the lower half of its industry. The industry median FCF Margin % is 3.34. Resonance Health's value of 0.41% is 87.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.34, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Resonance Health's current FCF Margin % of 0.41% is 87.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Resonance Health and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Resonance Health's current FCF Margin % is 0.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Resonance Health stock overvalued right now?
Based on GuruFocus' analysis, Resonance Health (ASX:RHT) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.12, compared to a current price of A$0.05 — trading 61.7% below its estimated fair value. The current FCF Margin % is 0.41% and 87.7% below the Healthcare Providers & Services industry median of 3.34. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Resonance Health (ASX:RHT), the current FCF Margin % is 0.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Resonance Health Business Description

Address 141 Burswood Road, Level 1, Burswood, Perth, WA, AUS, 6100
Resonance Health Ltd is engaged in the development and commercialisation of software-as-medical-device (SaMD) technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled environment. The Group's core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. The Company also has several AI-assisted SaMDs including FerriSmart, HepaFatSmart, and LiverSmart. Its business segments are; SaMD1 which derives key revenue, Corporate, TrialsWest, and Resonance Clinica. Geographically, it generates maximum revenue from the Asia Pacific region and the rest from North America, and Europe, Middle East and Africa (EMEA) regions.